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• Infections are a frequent and possibly life-threatening problem in intensive care unit patients, and
antibiotic therapy is one of the cornerstones of the treatment.
• Therapeutic drug monitoring has been proposed to optimise antibiotic therapy but measuring
tissue concentrations remains difficult (1).
• The ExaBreath® device (SensAbues AB, Sollentuna, Sweden) has proven reliable for collecting
exhaled breath to quantify recreational drugs but has not been evaluated for measuring antibiotic
concentrations (2,3).
Introduction
Objective
• To explore the feasibility and safety of the ExaBreath®-device to determine antibiotic
concentrations in exhaled air.
• Ten spontaneously breathing patients treated with piperacillin/tazobactam or meropenem and
considered capable exhaling for 3 minutes through the ExaBreath®-device participated.
• Patients exhaled through the device until the control container was full (which equates to 30L of
exhaled breath), or until the patientwanted to stop.
• Samples were analyzed using liquid chromatography high resolution mass spectrometry. The
devices were opened and the filters were extracted with 2 mL 80:20 4% NaCl in water:isopropanol
containing piperacillin-D5 and meropenem-D6 as internal standards. The analysis was performed
on a Thermo Q-Exactive.
Methods
• Eight patients were treated with piperacillin/tazobactam, 2 with meropenem.
• Six out of 10 patients were able to exhale in a standardized way in the device. The remaining 4 did
not exhale correctly, were tired or the control container filled too slowly.
• No complications related to the procedure occurred.
• Piperacillin and meropenem are present in the exhaled air in the pg to ng/filter range.
Results
• This pilot trial confirmed that it is possible to use the ExaBreath®-device in critically ill
patients, although there were some practical difficulties in exhaling in a coordinated way in
4 out of 10 patients.
• Antibiotic concentrations were detectable in exhaled breath in the pg to ng/filter range.
• Further research is necessary to evaluate the potential use of the ExaBreath device in the
treatment of infections in the ICU. Sampling patients on mechanically ventilated patients
could bypass the difficulties in exhaling in a non-standardized way.
Conclusion
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